Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast
Autori principali: Schneeweiss, Andreas, Ettl, Johannes, Lüftner, Diana, Beckmann, Matthias W., Belleville, Erik, Fasching, Peter A., Fehm, Tanja N., Geberth, Matthias, Häberle, Lothar, Hadji, Peyman, Hartkopf, Andreas D., Hielscher, Carsten, Huober, Jens, Ruckhäberle, Eugen, Janni, Wolfgang, Kolberg, Hans Christian, Kurbacher, Christian M., Klein, Evelyn, Lux, Michael P., Müller, Volkmar, Nabieva, Naiba, Overkamp, Friedrich, Tesch, Hans, Laakmann, Elena, Taran, Florin-Andrei, Seitz, Julia, Thomssen, Christoph, Untch, Michael, Wimberger, Pauline, Wuerstlein, Rachel, Volz, Bernhard, Wallwiener, Diethelm, Wallwiener, Markus, Brucker, Sara Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Corrigendum
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878444/
https://ncbi.nlm.nih.gov/pubmed/33413981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.12.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi